Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are females at least 18 years of age in good general health who are not menopausal.~* Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria:~* Off-white (milky or gray), thin, homogeneous vaginal discharge~* Vaginal pH ≥ 4.7~* Presence of clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount~* A positive 10% KOH Whiff test.~* Have a Gram stain slide Nugent score ≥ 4 at the Baseline visit (Day 1)~Exclusion Criteria:~* Are pregnant, lactating, or planning to become pregnant during the study.~* Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex.~* Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline visit (Day 1).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYM-1219 Low Dose (Type: EXPERIMENTAL): Administered orally
- SYM-1219 High Dose (Type: EXPERIMENTAL): Administered orally
- Placebo (Type: PLACEBO_COMPARATOR): Administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).